No Data
Hong Kong stocks movement | REMEGEN (09995) fell nearly 5% in the afternoon, with annual losses slightly narrowing to 1.468 billion yuan. The company is recently facing multiple bearish factors.
REMEGEN (09995) fell over 4% in the afternoon. As of the time of writing, it has dropped by 3.89%, priced at 17.28 Hong Kong dollars, with a trading volume of 76.9238 million Hong Kong dollars.
RemeGen's 2024 Loss Narrows as Revenue Surges 58%
Rongchang Biotech: Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2024 Annual Results Express Announcement
Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2024 Annual Results Express Announcement
REMEGEN: INSIDE INFORMATION-2024 ANNUAL RESULTS UPDATE ANNOUNCEMENT
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
